Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemia. (Q40519355)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26389849%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

title

Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26389849%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26389849%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Matt E Kalaycio

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26389849%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

O George Negrea

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26389849%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Kanti R Rai

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26389849%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Rashid M Abbasi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26389849%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Heather Horne

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26389849%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

William A Wegener

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26389849%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

David M Goldenberg

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26389849%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

publication date

19 October 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26389849%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26389849%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26389849%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26389849%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

page(s)

803-811

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26389849%20AND%20SRC:MED&resulttype=core&format=json

Rituximab in chronic lymphocytic leukemia

24 February 2020

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1085531

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1085531

Rituximab dose-escalation trial in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1085531

Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1085531

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1085531

Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1085531

U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1085531

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1085531

Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1085531

Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1085531

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1085531

Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1085531

Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1085531

Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1085531

Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1085531

Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1085531

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1085531

Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1085531

Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1085531

Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1085531

Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1085531

Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1085531

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1085531

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1085531

10.3109/10428194.2015.1085531

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26389849%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26389849%20AND%20SRC:MED&resulttype=core&format=json